Skip to main content

Table 5 Univariate and multivariable analyses assessing factors associated with pfmdr1 N86Y mutant allele at delivery

From: Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso

Variables N OR (95%CI) P AOR (95%CI) P
Parasite density 116     
 < Median (2,237.2 parasites/µl) 43 1    
 ≥ Median 73 4.03 (0.86–19.0) 0.08 5.5 (1.07–28.0) 0.04
Number of SP doses 116     
 < 3 78 1    
 ≥ 3 38 0.13 (0.02–1.07) 0.06 0.25 (0.07–0.92) 0.04
MiP preventive strategy 116     
 IPTp-SP 56 1    
 CSST/IPTp-SP 60 0.92 (0.30–2.83) 0.89   
Triple dhfr 51/59/108 mutation
 No 25 1    
 Yes 58 1.64 (0.30–8.95) 0.57   
AL treatment during pregnancy
 0 51 1    
  ≥ 1 65 0.39 (0.12–1.24) 0.10 0.25 (0.07–0.89) 0.03
Timing Al treatment to delivery
 No treatment 51 1    
 4 to 28 days 20 0.51 (0.10–2.64) 0.43   
 29 to 42 days 21 0.001 (0.001–1.01) 0.96   
 43 to 63 days 13 0.39 (0.04–3.38) 0.39   
  ≥ 64 days 11 1.04 (0.19–5.64) 0.97   
Age 116     
  < Mean (25.2 years ± 6.4 58 1    
 ≥ Median 58 0.88 (0.28–2.71) 0.82   
Gravidity 116     
 Primi-secundigravidae 55 1    
 Multigravidae 61 0.64 (0.21–1.98) 0.44   
Malaria episode 116     
 < 2 37 1    
 ≥ 2 79 0.82 (0.25–2.65) 0.74   
Malaria infection at ANC-1 and at delivery
 No 85 1    
 Yes 31 1.62 (0.50–5.28) 0.42   
Haemoglobin level at delivery 113     
 ≥ Mean 11.5 g/dl ± 1.7 55 1    
 < Mean 58 0.68 (0.22–2.10) 0.50   
 ITN usage 101     
 No 34 1    
 Yes 67 0.46 (0.13–1.55) 0.21